SUNPHARMASun Pharmaceutical Industries Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · CRISIL: AAA (Developing)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 1.6 this quarter.
Momentum from moving averages, Supertrend and RSI.
1 forensic issue found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
1 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹16199 Cr | ₹1995 Cr | 24.60% | 12.32% | ₹8.30 | 43.3x |
| Q1 FY2027 | ₹15300 Cr | ₹2901 Cr | 24.05% | 18.96% | ₹12.10 | 42.1x |
| Q4 FY2026 | ₹14612 Cr | ₹2710 Cr | 21.75% | 18.54% | ₹11.30 | 42.3x |
| Q3 FY2026 | ₹15521 Cr | ₹3381 Cr | 27.17% | 21.79% | ₹14.00 | 54.9x |
| Q2 FY2026 | ₹14478 Cr | ₹3125 Cr | 26.23% | 21.58% | ₹13.00 | 42.7x |
| Q1 FY2026 | ₹13851 Cr | ₹2293 Cr | 26.00% | 16.55% | ₹9.50 | 43.4x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.